Analysts Are Mostly Positive on Jazz Pharmaceuticals in July

In June, Jazz Pharmaceuticals (JAZZ) entered into an agreement with TerSera Therapeutics to sell its rights associated with Prialt to TerSera. As per the terms of the agreement, TerSera will provide employment opportunities to the majority of the Jazz Pharmaceuticals’ employees associated with Prialt. Presently, Prialt is the only therapy approved by the FDA for the treatment of chronic pain in adult individuals in need of intrathecal therapy.